Vector Development Lab


Merger of Vector Development Laboratory and Gene Vector Core


We are excited to announce the merger of the Vector Development Laboratory of the Center for Cell and Gene Therapy with the Gene Vector Core, an Institutional Advanced Technology Core.  

Effective Nov. 1, 2021, the merged core, that retains the name Gene Vector Core, will provide expanded services available to all national and international investigators that combines the technologies and resources of the two facilities under a single operational organization. A list of basic services includes the following:

Viral Vector Production

  • Adeno-Associated Viral Vectors (AAV)
    AAV serotypes: 1, 2, 5, 6, 7, 8, 9, 10, PHP.eB, PHP.S, 7M8, 2-Retro, DJ and DJ8
  • Helper-Dependent Adenoviral Vectors (HDAd)
    HDAd serotypes: 2, 5, 5/35, 5/11, and custom targeted
  • First Generation Adenoviral Vectors (Ad)
    FGAd5, FGAd5F35
  • VSVG-Pseudotyped Lentiviral Vectors (LV)
    (LV) with second, third, and fourth-generation packaging systems, and 2nd and 3rd generation non-integrating LVs
  • Retroviral Vectors (RV)
    Ecotropic, amphotropic, and pantropic VSVG-Pseudotyped
  • G-Deleted Rabies

Supporting Services

  • Subcloning and scaled plasmid preparation for viral vector production
  • Variety of “prepackaged, off the shelf and ready to use” Adenoviral vectors
    (Expression Features include: Cre, eGFP, Cre-eGFP, LacZ, Luciferase, dsRed, and empty control)
  • Quality Control Assays
    Viral titers, HPLC full: empty capsid ratio analysis, tests for RCA, sterility endotoxin and mycoplasma

The newly merged core is co-directed by Kazuhiro Oka, Ph.D. (current Gene Vector Core Director) and Corinne Sonnet, Ph.D. (Director of the former Vector Development Lab). As a support group for the BCM research community we welcome ideas to improve services as well as to develop new viral vectors.

Back to topback-to-top